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AbstrAct
We hypothesized that women inheriting one germline mutation of the BRCA1 
gene (“one-hit”) undergo cell-type-specific metabolic reprogramming that supports 
the high biosynthetic requirements of breast epithelial cells to progress to a fully 
malignant phenotype. Targeted metabolomic analysis was performed in isogenic pairs of 
nontumorigenic human breast epithelial cells in which the knock-in of 185delAG mutation 
in a single BRCA1 allele leads to genomic instability. Mutant BRCA1 one-hit epithelial cells 
displayed constitutively enhanced activation of biosynthetic nodes within mitochondria. 
This metabolic rewiring involved the increased incorporation of glutamine- and glucose-
dependent carbon into tricarboxylic acid (TCA) cycle metabolite pools to ultimately 
generate elevated levels of acetyl-CoA and malonyl-CoA, the major building blocks 
for lipid biosynthesis. The significant increase of branched-chain amino acids (BCAAs) 
including the anabolic trigger leucine, which can not only promote protein translation via 
mTOR but also feed into the TCA cycle via succinyl-CoA, further underscored the anabolic 
reprogramming of BRCA1 haploinsufficient cells. The anti-diabetic biguanide metformin 
“reversed” the metabolomic signature and anabolic phenotype of BRCA1 one-hit cells 
by shutting down mitochondria-driven generation of precursors for lipogenic pathways 
and reducing the BCAA pool for protein synthesis and TCA fueling. Metformin-induced 
restriction of mitochondrial biosynthetic capacity was sufficient to impair the tumor-
initiating capacity of BRCA1 one-hit cells in mammosphere assays. Metabolic rewiring 
of the breast epithelium towards increased anabolism might constitute an unanticipated 
and inherited form of metabolic reprogramming linked to increased risk of oncogenesis 
in women bearing pathogenic germline BRCA1 mutations. The ability of metformin to 
constrain the production of mitochondrial-dependent biosynthetic intermediates might 
open a new avenue for “starvation” chemopreventive strategies in BRCA1 carriers.
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INtrODUctION
Germline mutations of the BRCA1 gene confer a breast 
cancer risk in women 10- to 20-fold higher than in those 
with the wild-type gene [1–3]. Although hereditary tumors 
in women that carry BRCA1 mutations account for only a 
small percentage (5–10%) of breast cancers [4], the risk of 
developing the disease throughout the lifetime is much higher 
(up to 85%) in BRCA1 mutation carriers than in noncarriers. 
According to the “two-hit” hypothesis proposed more than 
40 years ago by Knudson [5], individuals carrying a germline 
mutation in one copy of the BRCA1 gene require just one 
additional mutation in the same gene in an otherwise normal 
breast epithelial cell for malignant transformation. However, 
BRCA1-mediated tumorigenesis apparently contradicts the 
original “two-hit” theory conformed by other familial cancer 
syndromes, in which consecutive deletion of two alleles 
accelerates tumorigenesis. Paradoxically, the absence of both 
BRCA1 alleles in adult human cells induces cell proliferation 
defects that lead in the main to cell death. Moreover, the bi-
allelic inactivation of BRCA1 commonly observed in tumors 
of BRCA1 cancer patients results in early embryonic lethality 
when reproduced in animal models [6–8]. This raises the 
question, how can tumor cells survive with loss of both 
BRCA1 alleles?
Following biallelic, homozygous inactivation of 
BRCA1, pre-cancerous epithelial cells must amass additional 
genetic alterations on other genome guardian genes to 
survive. Accumulating evidence suggests that breast cancer 
predisposition upon inactivation of a single BRCA1 allele is 
caused by the so-called phenomenon of haploinsufficiency 
associated with heterozygosity [9–20], which results in 
genomic instability in breast epithelial cells [13, 14, 17, 
20]. This in turn may promote additional genetic changes in 
BRCA1 heterozygous cells, including the acquisition of new 
mutations that will precede and be permissive with the loss 
of BRCA1 (e.g., p53, ATM and CHK2). The requirement of 
this “extra-hit”, although incongruous from the viewpoint 
of familial tumorigenesis mediated by a tumor suppressor 
gene such as BRCA1, appears to enable cancer-prone BRCA1 
“one-hit” cells to evade the cell death processes that would 
otherwise occur upon loss of the remaining wild-type allele. 
While studies to identify genetic alterations, particularly 
activating changes, are warranted to better understand how the 
properties of BRCA1 haploinsufficiency influence the restricted 
tissue distribution of BRCA1 tumorigenesis, it is important to 
consider that breast malignancy can occur early in women with 
a germline BRCA1 mutation, whereas other BRCA1 mutation 
carriers develop disease much later or not at all [21]. From 
a strictly genetic perspective, if genetic instability caused by 
loss of BRCA1 allows the acquisition of mutations in critical 
checkpoint genes during puberty, this phenomenon would 
enable rare BRCA1 null cells to escape death and proliferate, 
leading to early breast cancer onset. If a majority or all cells 
with somatic inactivation of the remaining wild-type BRAC1 
allele succumb to checkpoint-mediated cell death, tumors 
would occur much later in the life of a woman with an inherited 
BRCA1 mutation. Alternatively, the incomplete penetrance 
associated with inherited BRCA1 mutations might reflect 
the fact that non-genetic modifiers have an important role in 
determining cancer risk among BRCA1 carriers. Although 
reproductive, dietary and lifestyle factors remain controversial 
with regards to their ability to influence BRCA1-related cancer 
risk [22–25], the common assumption that the fundamental 
mechanism(s) underlying breast cancer predisposition are 
expected to be different in BRCA1 mutation carriers than in the 
general population further complicates the scenario. 
By considering metabolic networks that could reconcile 
both genetic and nongenetic causal mechanisms in BRCA1-
driven tumorigenesis [16, 26–30], we herein tested the 
challenging hypothesis that BRCA1 haploinsufficiency drives 
metabolic rewiring in breast epithelial cells, acting as an early 
but suppressible “hit” that pushes BRCA1 one-hit cells toward 
malignant transformation. On the one hand, metabolic analyses 
of human cancers are beginning to indicate that mitochondrial 
damage and altered metabolism can precede malignancy 
[31–33]. On the other hand, induction of genomic instability 
comes at the cost of significant stress, which obliges cells to 
modify their energy use to provide adaptation against genetic 
changes as well as to promote their survival and growth 
[34–36]. Thus, normal breast epithelial cells bearing a single 
inherited “hit” in BRCA1 might become pre-equipped with a 
metabolic phenotype capable of supporting the high energetic 
and anabolic requirements for progression to a fully malignant 
phenotype. We present strong evidence for an unforeseen 
one-hit inherited metabolic trait linked to increased risk for 
oncogenesis in women with pathogenic germline BRCA1 
mutations that might be suppressible by the anti-diabetic drug 
metformin. 
rEsULts
Mutation of a single BRCA1 allele dramatically 
alters the metabolomic signature of normal-like 
breast epithelial cells
We utilized our recently developed targeted 
metabolomics platform coupling gas chromatography 
with quadrupole time-of-flight mass spectrometry and 
an electron impact source (GC-EI-QTOF-MS), which 
allows the simultaneous measurement of 30 selected 
metabolites representative of the catabolic and anabolic 
status of key metabolic nodes. These metabolites include 
not only representatives of glycolysis and the mitochondrial 
tricarboxylic acid (TCA) cycle, but also other biosynthetic 
routes such as pentose phosphate pathway, amino acid 
metabolism and de novo fatty acid biogenesis [37, 38]. 
To model BRCA1 haploinsufficiency, we employed 
a well-defined experimental system using MCF10A breast 
epithelial cells, a spontaneously immortal and genetically 
stable basal-like model with wild-type p53. A common 
pathogenic mutation, 185delAG, a 2-bp deletion in the coding 
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region close to the N-terminus, was introduced into BRCA1 
by gene targeting [14; Figure 1, top]. This heterozygous 
mutation leads to haploinsufficiency and genomic instability 
in MCF10A cells, and therefore accurately mimics the cell-
autonomous consequences of one-hit BRCA1 inactivation. 
Metabolite-based clustering obtained by partial least squares-
discriminant analysis (PLS-DA) model revealed a clear and 
significant separation between BRCA1185delAG/+ heterozygous 
cells and parental BRCA1+/+ cells in two-dimensional (2D) 
score plots (Figure 1, bottom). 
Heatmap visualization, commonly used for 
unsupervised clustering, revealed distinct segregation 
of metabolites in BRCA1185delAG/+ and BRCA1+/+ groups 
(Figure 2, left), pointing to a metabolic signature associated 
with the human BRCA1 mutation carrier state. In 
general, cellular metabolites related to a highly anabolic 
(biosynthetic) phenotype were more overrepresented 
in BRCA1185delAG/+ cells than in BRCA1+/+ cells, which 
significantly upregulated metabolites related to an 
oxidative phenotype (Figure 3). Accordingly, when the 
distinct metabolites between groups were selected with the 
criterion of variable importance in the projection (VIP ≥ 1) 
in the PLS-DA model, several coenzyme A (CoA) derivatives, 
such as acetyl-CoA, succinyl-CoA, and particularly malonyl-
CoA, as well as the branched-chain amino acids (BCCAs) 
valine, isoleucine, and leucine, were significantly higher in 
BRCA1185delAG/+ cells than in BRCA1+/+ cells (Figure 2, right).  
the anti-diabetic biguanide metformin reduces 
tumor-initiating capacity of breast epithelial BRCA1 
one-hit cells
Because metformin has attracted interest as an 
antitumor agent in cancer prevention and treatment [39–53], 
we explored the possible impact of metformin treatment on 
metabolic rewiring induced by pathogenic mutation of a single 
BRCA1 allele. Although both BRCA1185delAG/+ and BRCA1+/+ 
isogenic cells exhibited dose-dependent proliferative arrest 
in response to increasing concentrations of metformin as 
determined by MTT uptake, BRCA1185delAG/+ cells were more 
sensitive to the cytostatic effects of metformin than BRCA1+/+ 
parental cells (Figure 4A, left). 
BRCA1 is involved in regulating stemness and 
differentiation in stem and breast progenitor cells [54–57]. 
Accordingly, BRCA1 haploinsufficiency increases three-
dimensional clonal growth and proliferation of primary 
mammary epithelial cells from BRCA1 mutation carriers. As 
one of the properties of stem/progenitor cells is their ability 
to survive, proliferate and differentiate under anchorage-
independent conditions and generate spheroid structures [58], 
we tested the ability of BRCA1185delAG/+ and BRCA1+/+ cells to 
form tumorspheres (mammospheres) in suspension culture in 
the presence of metformin. Mammosphere forming-efficiency 
(MSFE) was calculated by dividing the number of sphere-like 
structures formed after 7 days (diameter > 50 μm) by the 
original number of cells seeded. A significantly higher number 
of bona fide mammospheres were formed from nontreated 
BRCA1185delAG/+ one-hit epithelial cells than nontreated 
BRCA1+/+ cells (Figure 4A, right), strongly suggesting that 
BRCA1 haploinsufficiency led to a significant expansion of 
the stem cell-like population. This stronger spheroid formation 
capacity of BRCA1185delAG/+ cells was significantly and dose-
dependently reduced by metformin, whereas baseline MSFE 
of BRCA1+/+ parental cells remained largely unresponsive to 
the drug (Figure 4A, right). Metformin-induced suppression 
of mammosphere formation (e.g., ≈50% reduction at 1 μmol/L 
metformin) was not attributed to non-specific toxic effects 
since cell viability in monolayer cultures remained as high 
as 75 ± 11% in the presence of an identical concentration of 
metformin (Figure 4A, left).
Metformin suppresses mitochondrial-dependent 
production of biosynthetic intermediates in BRCA1 
haploinsufficient cells
We next explored whether the ability of metformin 
to reduce tumor-initiating capacity in BRCA1 one- hit 
cells correlated with a capacity to alter the highly anabolic 
(biosynthetic) signature driven by BRCA1 haploinsufficiency. 
PLS-DA models revealed a significant separation between 
untreated and metformin-treated breast epithelial cells 
regardless of their BRCA1 status (Figure 4B). Thus, 
we speculated that the ability of metformin to suppress 
mammosphere formation in BRCA1 one-hit cells related to 
its ability to specifically deactivate biosynthetic mitochondrial 
nodes in BRCA1 one-hit cells but not in BRCA1+/+ cells. 
A general screen of the 30 selected metabolites using 
Heatmap visualization showed distinct segregation and 
revealed the ability of metformin to reverse the metabolomic 
signature and anabolic phenotype of mutant BRCA1 one-hit 
cells by: a) shutting down mitochondria-driven generation 
of lipogenic precursors, and b) reducing the pool of BCAAs 
for protein synthesis and/or anaplerotic fueling of TCA 
cycle metabolism (Figure 5, top). When VIP scores ≥ 1 in 
the PLS-DA model were used to maximize the difference of 
metabolic profiles between untreated and metformin-treated 
BRCA1185delAG/+ groups, it was noteworthy that the subset of 
metabolites majorly impacted by metformin included the 
basic building blocks for the de novo synthesis of fatty acids 
malony-CoA and acetyl-CoA, the TCA metabolites succinyl-
CoA and α-ketoglutarate, and the end-products of glycolysis 
lactate and pyruvate (Figure 5, top). A largely different 
metabolic rearrangement occurred after metformin treatment 
of BRCA1+/+ cells (Figure 5, bottom), strongly suggesting 
that metabolic responses to metformin-induced inhibition of 
complex I-dependent mitochondrial respiration depended on 
the intrinsic engagement of a given cell type to mitochondrial 
metabolism [59, 60]. 
Quantitative assessment of metabolite concentrations 
confirmed that treatment with metformin fully suppressed (> 
90% reduction) the major accumulation (≈162-fold increase) 
of malonyl-CoA and acetyl-CoA (23-fold increase) induced 
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by BRCA1185delAG/+ mutation (Table 1, Figure 6) Similarly, 
treatment with metformin reduced, by ≈90%, the 27-fold 
accumulation of succinyl-CoA and, by 60%, the levels of 
α-ketoglutarate in BRCA1185delAG/+ cells (Table 1). Although 
less dramatically, 1 mmol/L metformin reduced by up to 
40% the 5-, 7- and 6-fold accumulation of the BCAAs valine, 
leucine, and isoleucine, respectively, in BRCA1185delAG/+ 
cells. Conversely, metformin treatment increased, by ≈4- 
and 5-fold, the intracellular levels of lactate and pyruvate in 
BRCA1185delAG/+ cells, respectively. 
Although the key carbon donor for de novo fatty acid 
synthesis, malonyl-CoA, remained one of the most affected 
metabolites in metformin-treated BRCA1+/+ cells, it was 
noteworthy that this treatment triggered a largely different 
metabolic rearrangement when compared with BRCA1185delAG/+ 
cells (Figure 7). Moreover, although metformin treatment of 
BRCA1185delAG/+ cells failed to restore the metabolic portrait 
originally exhibited by BRCA1+/+ cells, a global assessment 
of untreated BRCA1+/+, metformin-treated BRCA1+/+, untreated 
BRCA1185delAG/+, and metformin-treated BRCA1185delAG/+ classes 
Figure 1: Metabolomic profiling of BRCA1 haploinsufficient breast epithelial cells. Top. Inactivating mutation of a single 
BRCA1 allele leads to haploinsufficiency, which results in genomic instability in the spontaneously immortalized MCF10A cell line [14]. 
Bottom. 2D PLS-DA models of the GC-EI-QTOF-MS-based metabolomic profiling for the BRCA1185delAG/+ haploinsufficient and BRCA1+/+ 
wild-type cell groups.
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table 1: concentration (in µM/mg of protein ± sEM) and fold change of bioenergetics metabolites 
in parental BRCA1+/+ and their BRAC1185delAG/+ haploinsufficient derivatives
Metabolite BRCA1+/+ BRCA1+/– Fold-change[BRCA1+/−/BRCA1+/+]
Malonyl-coA Control 0.0016 ± 0.0002 (1.0) 0.26 ± 0.05 (1.00) [162.5]
+ 1 mM MET N.D. 0.01658 ± 0.0007 (0.06) -
succinyl-coA Control 0.012 ± 0.001 (1.0) 0.32 ± 0.07 (1.0) [26.7]
+ 1 mM MET 0.012 ± 0.002 (1.0) 0.035 ± 0.003 (0.1)
Acetyl-coA Control 0.015 ± 0.001 (1.0) 0.34 ± 0.09 (1.00) [23]
+ 1 mM MET 0.0122 ± 0.0006 (0.8) 0.032 ± 0.001 (0.09)
3-Hydroxybutyrate Control 5.2 ± 0.4 (1.0) N.D. -
+ 1 mM MET 5.2 ± 0.2 (1.0) N.D. -
3-Phosphoglycerate Control 2.9 ± 0.2 (1.0) 2.2 ± 0.2 (1.0) [0.8]
+ 1 mM MET 1.2 ± 0.1 (0.4) 2.1 ± 0.5 (1.0)
6-Phosphogluconate Control 6.9 ± 0.2 (1.0) 6.3 ± 0.1 (1.0) [0.9]
+ 1 mM MET 7.2 ± 0.8 (1.0) 10.1 ± 0.2 (1.6)
Aconitate Control 0.31 ± 0.02 (1.0) 0.49 ± 0.01 (1.0) [1.6]
+ 1 mM MET 0.31 ± 0.05 (1.0) 0.34 ± 0.01 (0.7)
α-ketoglutarate Control 0.625 ± 0.003 (1.0) 1.04 ± 0.09 (1.0) [1.7]
+ 1 mM MET 0.56 ± 0.05 (0.9) 0.37 ± 0.04 (0.4)
Alanine Control 112 ± 11 (1.0) 277 ± 21 (1.0) [2.5]
+ 1 mM MET 49 ± 4 (0.4) 261 ± 19 (0.9)
Aspartate Control 112 ± 19 (1.0) 258 ± 11 (1.0) [2.3]
+ 1 mM MET 72 ± 6 (0.6) 224 ± 18 (0.9)
citrate Control 7.0 ± 0.5 (1.0) 12.7 ± 0.4 (1.0) [1.8]
+ 1 mM MET 7.9 ± 0.9 (1.1) 11.6 ± 0.7 (0.9)
Fructose 
1,6-bisphosphate Control 0.55 ± 0.01 (1.0) 0.35 ± 0.05 (1.0) [0.6]
+ 1 mM MET 0.21 ± 0.03 (0.4) 0.44 ± 0.07 (1.3)
Fructose 6-phosphate Control 1.24 ± 0.09 (1.0) 1.73 ± 0.06 (1.0) [1.4]
+ 1 mM MET 0.6 ± 0.1 (0.5) 2.03 ± 0.08 (1.2)
Fumarate Control 4.0 ± 0.2 (1.0) 3.8 ± 0.2 (1.0) [1.0]
+ 1 mM MET 3.7 ± 0.5 (1.0) 4.0 ± 0.5 (1.0)
Glyceraldehyde 
3-phosphate Control 2.6 ± 0.4 (1.0) 2.6 ± 0.2 (1.0) [1.0]
+ 1 mM MET 2.9 ± 0.4 (1.1) 2.6 ± 0.5 (1.0)
Glucose Control 7.6 ± 0.7 (1.0) 5.66 ± 0.04 (1.0) [0.7]
+ 1 mM MET 1.6 ± 0.2 (0.2) 3.2 ± 0.5 (0.6)
Glucose 6-phosphate Control 2.7 ± 0.3 (1.0) 2.6 ± 0.3 (1.0) [1.0]
+ 1 mM MET 1.2 ± 0.2 (0.4) 2.3 ± 0.4 (0.9)
Glutamate Control 21.8 ± 0.4 (1.0) 126 ± 2 (1.0) [5.8]
+ 1 mM MET 5.9 ± 0.9 (0.3) 78 ± 4 (0.6)
Glutamine Control 7.5 ± 0.4 (1.0) 13.9 ± 0.4 (1.0) [1.8]
+ 1 mM MET 7.4 ± 1.5 (1.0) 13.4 ± 0.3 (1.0)
Isoleucine Control 15 ± 3 (1.0) 87 ± 4 (1.0) [5.8]
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based on the VIP parameter once again revealed that the CoA 
derivatives malonyl-CoA, succinyl-CoA, and acetyl-CoA, and 
the BCCAs leucine and isoleucine were the key metabolites 
responsible for separation of all the metabolomic classes 
(Figure 7). 
Metformin differentially impacts the capacity of 
normal-like and BRCA1 haploinsufficient cells to 
oxidize glucose and glutamine 
Because mitochondrial access to different fuels such 
as glucose and glutamine significantly impacts a variety of 
biological processes, we assessed whether BRCA1+/+ and 
BRCA1185delAG/+ breast epithelial cells might differentially 
adjust fuel oxidation to match nutrient availability while 
meeting energy demand. Taking advantage of the Seahorse XF 
Mito Fuel Flex Test, a comprehensive method for measuring 
mitochondrial fuel usage in live cells, we measured the 
dependency (i.e., the requirement for a specific fuel to meet 
metabolic demand), capacity (i.e., the ability to use a specific 
fuel to meet energy demand), and flexibility (i.e., the difference 
between the amount they need and the amount they could 
use) of BRCA1+/+ and BRCA1185delAG/+ breast epithelial cells 
to oxidize glucose and glutamine when pre-challenged with 
metformin (5 μmol/L, 24 h). BRCA1185delAG/+ breast epithelial 
cells exhibited a significantly lower capacity to use and 
increase the oxidation of glucose when trying to compensate 
for BPTES- and etomoxir-induced inhibition of alternative 
fuel pathways (i.e., glutamine oxidation and long chain fatty 
acid oxidation, respectively), a mitochondrial fuel usage that 
was further exacerbated when BRCA1 haploinsufficient cells 
were pre-exposed to metformin (Figure 8, left). Conversely, 
BRCA1185delAG/+ breast epithelial cells exhibited a significantly 
higher capacity to use and increase the oxidation of glutamine 
when trying to compensate for UK5099 and etomoxir-
induced inhibition of alternative fuel pathways (i.e., glucose 
oxidation and long chain fatty acid oxidation, respectively), a 
mitochondrial fuel usage that was further exacerbated when 
BRCA1 haploinsufficient cells were pre-exposed to metformin 
(Figure 8, right). 
Metformin reverts the activation of mTOR-related 
signaling in BRCA1 haploinsufficient cells 
To explore whether the apparent anabolic 
reprogramming of BRCA1 haploinsufficient cells involved 
the activation of signal transduction mechanisms linked to 
mTOR, we took advantage of commercially available slide-
based antibody arrays for the simultaneous assessment of 
18 well-characterized intracellular signaling molecules 
(Figure 9). BRCA1185delAG/+ breast epithelial cells exhibited 
a noteworthy hyperactivation of the oncogenic protein 
AKT, a well-known controller of protein synthesis at the 
+ 1 mM MET 13 ± 2 (0.9) 68 ± 7.4 (0.8)
Lactate Control 1638 ± 293 (1.0) 373 ± 16  (1.0) [0.2]
+ 1 mM MET 944 ± 125 (0.6) 1490 ± 115 (4.0)
Leucine Control 35 ± 7 (1.0) 260 ± 12 (1.0) [7.4]
+ 1 mM MET 32 ± 6 (0.9) 161 ± 14 (0.6)
Malate Control 2.06 ± 0.05 (1.0) 2.2 ± 0.1 (1.0) [1.1]
+ 1 mM MET 1.834 ± 0.3 (0.9) 2.7 ± 0.2 (1.2)
Oxaloacetate Control 39 ± 2 (1.0) N.D. -
+ 1 mM MET N.D. N.D.
Phosphoenolpyruvate Control 2.1 ± 0.3 (1.0) 1.5 ± 0.1 (1.0) [0.7]
+ 1 mM MET 1.7 ± 0.3 (0.8) 3.0 ± 0.3 (2.0)
Pyruvate Control 35 ± 6 (1.0) 7.7 ± 0.7 (1.0) [0.2]
+ 1 mM MET 8.0 ± 0.3 (0.2) 36 ± 4 (4.7)
ribose 5-phosphate Control 1.8 ± 0.3 (1.0) 1.9 ± 0.2 (1.0) [1.0]
+ 1 mM MET 1.5 ± 0.3 (0.8) 2.5 ± 0.2 (1.3)
serine Control 118 ± 18 (1.0) 338 ± 28 (1.0) [2.9]
+ 1 mM MET 59 ± 5 (0.5) 301 ± 27 (0.9)
succinate Control 24 ± 3 (1.0) 22 ± 4 (1.0) [0.9]
+ 1 mM MET 29 ± 6 (1.2) 24 ± 4 (1.1)
Valine Control 15 ± 1 (1.0) 74 ± 4 (1.0) [4.9]
+ 1 mM MET 19 ± 3 (1.3) 48 ± 5 (0.6)
Decimals were set according to the first significant digit of the measured SEM.
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level of translation initiation and ribosome biogenesis 
[61, 62], when compared to BRCA1+/+ parental cells. The 
AKT/mTOR-related activation of protein synthesis driven 
by BRCA1 haploinsufficiency was confirmed by the 
hyperphosphorylation of the proline-rich AKT substrate of 
50 kDa (PRAS40) at Thr246 by AKT, which is known to act 
at the intersection of the AKT and mTOR-mediated signaling 
by relieving PRAS40 inhibition of the mTOR complex 1 
(mTORC1) [63–65]. Interestingly, a 48 h treatment with 
metformin fully suppressed the activation of the AKT/
mTOR-signaling network in BRCA1 haploinsufficient cells 
(Figure 9). Indeed, metformin-treated BRCA1185delAG/+ breast 
epithelial cells treatment failed to phosphorylate the pro-
apoptotic protein BAD at Ser112 and the multifunctional 
kinase GSK-3β at Ser9, an AKT-driven signaling that is 
known to inhibit BAD and GSK-3β activities to promote 
cell survival [66, 67]. 
DIscUssION
In addition to oncogenic mutations, a shift towards 
cancer-like metabolic changes including increased aerobic 
utilization of glucose to produce lactate mediated by glycolysis 
(Warburg effect) [68] and enhanced mitochondrial utilization 
of glucose and glutamine to sustain anabolic processes 
[69–78], might pre-set an idoneous metabolic stage for later 
mutations to drive tumorigenesis [31–33]. Here, we present 
evidence that inheritance of a mutated BRCA1 allele might 
expedite the establishment of a metabolic state compatible 
and “permissive” with the elevated genomic instability found 
in breast epithelial cells of women carrying a non-functional 
copy of BRCA1. 
To explore whether the one-hit event might be 
sufficient to shorten the time required for breast epithelial 
cells to become “pre-equipped” to support the metabolically-
demanding process of tumor formation, we utilized a GC-
EI-QTOF-MS-based metabolomic approach to examine 
whether metabolites involved in energy metabolism, 
including glycolysis, the TCA cycle, and pathways involved 
in metabolism of lipids, amino acids, and pentose phosphates 
were altered in response to “one-hit” BRCA1. Our present 
findings showing a dramatic accumulation of the acyl-CoA 
derivatives succinyl-CoA, acetyl-CoA, and malonyl-CoA 
accompanied by high levels of BCAAs in BRCA1185delAG/+ 
heterozygous cells, strongly suggest that germline mutation 
in a BRCA1 allele is sufficient to phenocopy multiple 
Figure 2: Inactivating mutation of a single BRCA1 allele leads to metabolic reprogramming towards an anabolic 
phenotype. Left. Heatmap visualization and hierarchical clustering analysis with MetaboAnalyst’s data annotation tool for the 
BRCA1185delAG/+ haploinsufficient and BRCA1+/+ wild-type cell groups. Rows: metabolites; columns: samples; color key indicates metabolite 
expression value (blue: lowest; red: highest). Right. VIP rank-score of quantified metabolites in BRCA1185delAG/+ haploinsufficient and 
BRCA1+/+ wild-type cell groups. Dashed blue box indicates metabolites that achieved VIP scores above 1.0. 
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bona fide oncogenic pathways to stimulate glucose- 
and glutamine-derived carbon atom flux, promote TCA 
metabolism and lipogenesis, and coordinate carbon and 
nitrogen metabolism across amino acids to likely stimulate 
mTOR-driven protein synthesis [73–86]. 
Compounds that interfere with early stages of cancer 
formation are particularly appropriate for mutation carriers 
and evidence indicates that risk reduction strategies focused 
on patients harboring germ-line BRCA1 mutations are 
effective [87–89]. In this regard, our present results established 
that pharmacological ablation of BRCA1 mutation-driven 
hyperactivation of mitochondrial-dependent biosynthetic 
activity was sufficient to reduce the tumor-initiating capacity 
of breast epithelial BRCA1 one-hit cells in mammosphere 
assays. Our findings that breast epithelial BRCA1 one-hit 
cells produced a greater number of mammospheres than 
controls extend previous studies showing that breast epithelial 
cells from BRCA1 mutation carriers form cell colonies in 
non-adherent conditions with greater efficiency than control 
epithelial cells [54– 57]. Importantly, we could establish a 
causal, functional relationship between the metabolic rewiring 
of BRCA1 one-hit cells and their increased mammosphere-
forming capacity, a surrogate measure of CSCs. Thus, we 
concluded that metformin treatment reduced the tumor-
initiating (self-renewal) capacity of breast epithelial BRCA1 
one-hit cells, whereas BRCA1 wild-type cells were mostly 
resistant at similar doses, which is indicative of a wide 
therapeutic index. Remarkably, the dissimilar responses of 
BRCA1 one-hit cells and BRCA1 wild-type cells to metformin 
in terms of stemness properties directly correlated with a more 
drastic and specific rearrangement of the anabolic phenotype in 
BRCA1 one-hit cells, supporting the notion that cells with high 
mitochondrial metabolism are more metabolically responsive 
to metformin [59, 60]. 
Mechanistically, our results indicated that metformin 
targeted the tumorigenic capacity of one-hit BRCA1 cells 
Figure 3: BRCA1 “one-hit”-induced metabolic changes in breast epithelial cells. Metabolites in BRCA1185delAG/+ haploinsufficient 
cells were extracted and quantitatively analyzed by GC-EI-QTOF-MS and compared with metabolites from control BRCA1+/+ isogenic 
parental cells. Significantly increased and decreased metabolites are shown using yellow-red and light blue-dark blue color scales, 
respectively.
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by starving mitochondria of the necessary metabolic 
intermediates required for anabolic metabolism. Our 
TCA metabolite screen revealed that metformin treatment 
significantly reduced the total abundance of α-ketoglutarate, 
accompanied by the suppression of malonyl-CoA 
generation, the major building block for lipid biosynthesis. 
Although it might be argued that the ability of metformin 
to interfere with the anaplerotic entry of glutamine into the 
TCA cycle can explain the increased sensitivity of BRCA1 
one-hit cells to its anti-tumor initiating capacity, it should be 
also acknowledged that metformin reduced glucose-derived 
acetyl-CoA entry into mitochondrial metabolism in BRCA1 
one-hit cells more dramatically than in BRCA1 wild-type 
cells. Indeed, BRCA1 one-hit cells treated with metformin 
had an increased fraction of total malate within the TCA 
cycle while also increasing the intracellular concentration of 
pyruvate and lactate. The reduced usage of pyruvate by the 
TCA cycle accompanied by increased generation of lactate 
clearly indicated that metformin treatment diverted pyruvate 
away from mitochondrial metabolism by increasing 
glycolysis activity in BRCA1 one-hit cells. Therefore, 
inhibition of complex I-dependent mitochondrial respiration 
by metformin in turn inhibits the overactive TCA cycle in 
BRCA1 one-hit cells, which accept less glucose carbon, 
favoring lactic acid production. In addition, metformin 
treatment also impedes the glutamine contribution to 
anaplerotic flux into the TCA cycle, and the previously 
argued adaptive response to metformin involving a shift in 
α-ketoglutarate metabolism towards reductive carboxylation, 
failed to replenish the high-levels of lipogenic acetyl-CoA 
induced by BRCA1 haploinsufficiency. Moreover, because 
valine and isoleucine contain carbons that form succinyl-
CoA, whereas the degradation of isoleucine and leucine 
forms acetyl-CoA, the ability of metformin to reduce the 
pool of BCAAs, which comprises almost 25% of the content 
of the average protein, might impede BRCA1 one-hit cells to 
meet their elevated demand for alanine and glutamine and 
protein synthesis by impairing BCCA-driven activation of 
mTOR and TCA fueling.
Tremendous progress has been made in the last 20 
years in understanding how monoallelic BRCA1 loss leads 
to defects in DNA damage response, chromatin organization, 
gene transcription, cell division, and protein and genome 
stability [90–92]. Nevertheless, it remains enigmatic why a 
mutation in a single copy of BRCA1 leads to rapid tumor 
onset in a very strict tissue- and cell-type-specific manner. 
Our present results identify an inherited form of metabolic 
reprogramming and provide a conceivable metabolic 
basis for the rapid cell- and tissue-specific predisposition 
of breast cancer development associated with BRCA1 
haploinsufficiency. The metabolomic signature distinguishing 
wild-type from BRCA1 haploinsufficient but otherwise 
isogenic breast epithelial cells reveals that a constitutively 
enhanced activation of mitochondrial-dependent biosynthesis 
becomes activated to sustain anabolic processes in mutant 
BRCA1 cells. Our findings add a new dimension to Sinclair’s 
original proposal of geroncogenesis [31], which states that 
normal decline in oxidative mitochondrial metabolism during 
aging constitutes an early and important “hit” that drives 
tumorigenesis. Our findings experimentally support our 
recent proposal that women carrying mutations in BRCA1 
might undergo a process of “accelerated geroncogenesis” 
in mammary epithelia [93]. The unanticipated ability of 
one germline BRCA1 hit to reprogram breast epithelial host 
metabolism towards increased anabolism should broaden 
our understanding of “gatekeeper” or “caretaker” tumor-
suppressor genes as well as improving our knowledge of 
the ultimate molecular requirements for BRCA1-driven 
Figure 4: treatment with the mitochondrial poison metformin suppresses mammosphere-initiating capacity of 
BRCA1 haploinsufficient breast epithelial cells. (A) Left. Relative cell viability of BRCA1185delAG/+ and BRCA1+/+ cells treated with 
graded concentrations of metformin. Cell viability was normalized to the condition with no metformin. Mean (circles) and SD (bars) 
were calculated from three biological replicates. Right. Seven-day MSFE of BRCA1185delAG/+ and BRCA1+/+ cells seeded in mammosphere 
medium in the absence or presence of graded concentrations of metformin and expressed as percentage mean (columns) ± SD (bars). 
Re-feeding of mammosphere cultures with metformin and/or sphere medium was performed on day 3 and 5. *P < 0.05; **P < 0.01 versus 
the corresponding controls. (b) Two-dimensional PLS-DA models of the GC-EI-QTOF-MS-based metabolomic profiling for the untreated 
and metformin-treated BRCA1185delAG/+ haploinsufficient and BRCA1+/+ wild-type cell groups (48 h treatment, 1 mmol/L metformin [MET]). 
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Figure 5: Metformin treatment specifically and significantly reverses the anabolic signature of BRCA1 haploinsufficient 
breast epithelial cells. Left panels. Heatmap visualization and hierarchical clustering analyses with MetaboAnalyst’s data annotation 
tool for the untreated and metformin-treated (1 mmol/L MET; 48 h) BRCA1185delAG/+ haploinsufficient (top) and BRCA1+/+ wild-type (bottom) 
cell groups. Rows: metabolites; columns: samples; color key indicates metabolite expression value (blue: lowest; red: highest). Right 
panels. VIP rank-score of quantified metabolites in untreated and metformin-treated BRCA1185delAG/+ haploinsufficient (top) and BRCA1+/+ 
wild-type (bottom) cell groups. Dashed blue box indicates metabolites that achieved VIP scores above 1.0. 
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Figure 6: Metformin-induced metabolic changes in BRCA1 haploinsufficient breast epithelial cells. Metabolites in 
metformin (MET)-treated BRCA1185delAG/+ haploinsufficient cells were extracted and quantitatively analyzed by GC-EI-QTOF-MS and 
compared with metabolites from either untreated BRCA1185delAG/+ haploinsufficient cells (top) or untreated BRCA1+/+ isogenic parental cells 
(bottom). Significantly increased and decreased metabolites are shown using yellow-red and light blue-dark blue color scales, respectively.
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Figure 7: Metformin treatment generates a new metabolomic signature in BRCA1 haploinsufficient breast epithelial 
cells. Left. Two-dimensional PLS-DA models to view the separation of the 4 groups (untreated BRCA1185delAG/+ haploinsufficient cells, 
metformin [MET]-treated BRCA1185delAG/+ haploinsufficient cells, untreated BRCA1+/+ wild-type cells, and metformin-treated BRCA1+/+ wild-
type cells) following GC-EI-QTOF-MS-based metabolomic profiling. Middle. Heatmap to view the agglomerative hierarchical clustering 
of the 4 groups analyzed with MetaboAnalyst’s data annotation tool. Rows: metabolites; columns: samples; color key indicates metabolite 
expression value (blue: lowest; red: highest). Right. VIP rank-score of quantified metabolites in the 4 groups. Dashed blue box indicates 
metabolites that achieved VIP scores above 1.0. 
Figure 8: Metformin treatment differentially impacts mitochondrial fuel usage in BRCA1 haploinsufficient breast 
epithelial cells. Figure shows the dependency, capacity, and flexibility of BRCA1185delAG/+ haploinsufficient and BRCA1+/+ wild-type cells 
to oxidize the mitochondrial fuels glucose (left) and glutamine (right) in the absence or presence of metformin. 
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Figure 9: Metformin suppresses BRCA1 haploinsufficiency-driven activation of the AKT/mTOR pathway. Figure shows 
representative chemiluminiscent array images of the PathScan Intracellular Signaling array kit revealing various phosphorylated signaling 
nodes in BRCA1185delAG/+ haploinsufficient and BRCA1+/+ wild-type cells cultured in the absence or presence of metformin. 
Figure 10: Mitochondrial-dependent biosynthesis: a therapeutically targetable feature of BRCA1-driven breast 
carcinogenesis. A schematic overview of the concept in the present study. (A) Original “two-hit” theory for the incidence of familial 
cancers proposed by Knudson [5]. (b) A modified two-hit model for BRCA1-mediated breast carcinogenesis suggested by the present 
study. Because BRCA1-null cells seem to require additional genetic changes for survival, BRCA1-mediated breast carcinogenesis 
may be considered in a distinct manner from other familial cancer syndromes that follow the two-hit theory, in which consecutive 
deletion of two alleles accelerates tumorigenesis. Inactivating mutations of a single BRCA1 allele leads to haploinsufficiency, which 
results in genomic instability in human breast epithelial cells. It has been suggested that genomic instability resulting from BRCA1 
haploinsufficiency is an early but not sufficient step for BRCA1-mediated breast carcinogenesis by allowing the accumulation of 
additional genetic changes that enable cancer progenitor cells to evade cell death that would otherwise occur upon loss of the remaining 
wild-type BRCA1 allele. We propose that BRCA1 haploinsufficiency is sufficient to produce significant and chronic changes in cellular 
metabolism by promoting a highly anabolic phenotype compatible and “permissive” with the elevated genomic instability present 
in BRCA1 heterozygous cells. If BRCA1 haploinsufficiency is exclusive to specific tissue types, such as breast epithelia, metabolic 
reprogramming towards mitochondrial-dependent biosynthesis in normal breast epithelial cells may provide a novel explanation for 
the restricted tissue distribution of BRCA1 carcinogenesis and could be potentially exploited to develop prophylactic therapies for 
BRCA1-related cancers. The anti-diabetic mitochondrial poison metformin inhibits complex I of the electron transport chain (ETC) 
[97, 98], which drastically restricts the production of mitochondrial-dependent biosynthetic intermediates by reducing the anaplerotic 
flux of glucose, glutamine, and likely BCCAs into the TCA cycle. The ability of metformin to restrict the production of mitochondrial-
dependent biosynthetic intermediates while depleting the pool of mTOR activating amino acids (e.g., leucine) might open a new avenue 
for “mitochondrial starvation” chemopreventive strategies in BRCA1 carriers. (AA: amino acids; Gln: glutamine; Glu: glutamate; 
α-KG: alpha-ketoglutarate). 
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neoplastic transformation in a tissue- and cell-type-specific 
manner. Although heterozygous BRCA1 inactivation itself 
might be insufficient for complete breast carcinogenesis, 
the acceleration of the rate at which an “anabolic threshold” 
would permit the survival and expansion of genomically 
altered breast epithelial cells might operate as a true 
oncogenic event of BRCA1 haploinsufficiency-driven breast 
carcinogenesis (Figure 10). Further studies are warranted to 
determine the ultimate role of BRCA1 haploinsufficiency-
driven metabolic reprogramming in the discrete evolutionary 
pathways occurring in BRCA1-associated breast tumors [94] 
and whether a similar metabolic facet should be contemplated 
when assessing the pathophysiology, consequences and 
therapeutic value of other well-known oncosuppressors. 
Because BRCA1 haploinsufficient cells display 
phenotypic alterations in cell-surface marker expression 
[56, 95] despite their normal histological appearance [56], 
metabolic rewiring of the breast epithelium towards increased 
anabolism can be employed to provide novel metabolic 
biomarkers in women bearing pathogenic germline BRCA1 
mutations. Moreover, the fact that BRCA1 haploinsufficiency 
might accelerate the geroncogenic trait that naturally occurs 
in the breast epithelium also provides a rationale for new 
preventive and therapeutic strategies based on drugs or 
energetic behavior tools aimed to halt the breast tissue- and 
epithelial cell-specific metabolic reprogramming that might 
occur in BRCA1 carriers. Our results indicate that metformin 
can limit the enhanced tumor-initiating capacity of mutant 
BRCA1 one-hit cells by starving them of the biosynthetic 
intermediates required for an efficient anabolic cell growth 
and survival. Together, our data support a recently proposed 
“substrate limitation” model of metformin action [59, 60], in 
which metformin restricts the production of mitochondrial-
dependent biosynthetic intermediates by reducing the 
anaplerotic flux of glucose, glutamine, and likely BCCAs, 
into the TCA cycle, leading to depletion of acetyl-CoA and 
malonyl-CoA required for de novo lipid biosynthesis and 
inhibition of mTOR-driven protein synthesis in anabolism-
addicted BRCA1 haploinsufficient cells (Figure 10). These 
observations can be exploited to develop new metformin-
based “starvation” strategies as chemopreventive and 
treatment options in BRCA1 carriers. 
MAtErIALs AND MEtHODs
cell lines 
Human BRCA1 (185delAG/+) MCF10A cells with 
heterozygous knock-in of a 2-bp deletion of BRCA1 resulting 
in a premature termination codon at position 39 and MCF10A 
isogenic parental cells were obtained from Horizon Discovery 
Ltd., Cambridge, UK (Cat# HD 101–018 and HD PAR-058, 
respectively). Cells were routinely grown in DMEM/F-12 
(Gibco, Life Technologies, Paisley, UK) including 2.5 mmol/L 
L-glutamine, and 15 mmol/L HEPES, supplemented with 5% 
horse serum (HS), 10 μg/ mL insulin, 20 ng/mL hEGF, 0.5 μg/
mL hydrocortisone and 0.1 μg/ mL cholera toxin. Cells were 
cultured as a monolayer at 37oC in a humidified atmosphere 
with 5% CO2. Cells were passaged every 3–5 days and split at 
80–90% confluency, approximately 1:6–1:10.
targeted Metabolomics 
Measurements of meta bolites obtained from 
heterozygous BRCA1185delAG/+ and BRCA1+/+ isogenic parental 
cells cultured in the absence or presence of 1 μmol/L metformin 
(48 h) were performed by employing a previously described 
simple and quantitative method based on gas chromatography 
coupled to quadrupole-time of flight mass spectrometry and an 
electron ionization interface (GC-EI-QTOF-MS) [37, 38]. 
Data analysis
Raw data were processed and compounds were detected 
and quantified using the Qualitative and Quantitative Analysis 
B.06.00 software (Agilent Technologies), respectively. 
MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/) was used 
to generate scores/loading plots and Heatmaps [96].
Cell viability assays 
The cell viability effects of metformin were determined 
using the standard colorimetric MTT reduction assay. For each 
treatment, cell viability was evaluated as a percentage using 
the following equation: (OD570 of the treated sample/OD570 of 
the untreated sample)×100.
Mammosphere culture and mammosphere-forming 
efficiency 
Single cell suspensions of BRCA1185delAG/+ and BRCA1+/+ 
cell lines were plated in 6-well tissue culture plates previously 
coated with poly-2-hydroxyethyl-methacrylate (Sigma, 
St. Louis, MO) to prevent cell attachment, at a density of 
1000 cells/mL in serum-free DMEM/F-12 supplemented 
with 1% L-glutamine, 1% penicillin/streptomycin, 2% 
B27 (Invitrogen, Carlsbad, CA), 20 ng/mL EGF (Sigma) 
and 20 ng/ mL FGFb (Invitrogen). The medium was made 
semi-solid by the addition of 0.5% methylcellulose (R&D 
Systems, Minneapolis, MN) to prevent cell aggregation. 
Mammosphere-forming efficiency (MSFE) was calculated 
as the number of sphere-like structures (diameter > 50 μm) 
formed after 7 days in the absence or presence of 1 mmol/L 
metformin, divided by the original number of cells seeded and 
expressed as a percentage (mean ± SD).
Mitochondrial oxidation of glucose and glutamine
Oxidation rates of glucose and glutamine were 
measured using an XFp Extracellular Flux Seahorse Analyzer 
(Seahorse Bioscience). BRCA1185delAG/+ and BRCA1+/+ cells 
(15,000/well) were treated with 1 mmol/L metformin for 24 h 
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prior to the star of the XFp Mito Fuel Flex Test kit, which was 
performed in accordance with manufacturer’s instructions. 
Each plotted value is the mean of at least 6 replicates and is 
normalized to Hoechst signal in each well. 
Pathscan sandwich immunoassay 
The PathScan® Intracellular Signaling array kit 
(Cell Signaling Technology, #7323) was used according 
to the manufacturer’s instructions. Briefly, overnight 
serum-starved BRCA1185delAG/+ and BRCA1+/+ cells cultured 
in the absence or presence of 5 mmol/L metformin for 
48 h in 5% HS were washed with ice-cold 1× phosphate-
buffered saline and lysed in 1× Cell Lysis buffer. The 
Array Blocking Buffer was added to each well and 
incubated for 15 min at room temperature. Subsequently, 
the lysate was added to each well and incubated for 2 h at 
room temperature. Subsequent to washing, the detection 
antibody cocktail was added to each well and incubated 
for 1 h at room temperature. Horseradish peroxidase 
(HRP)-linked streptavidin was added to each well and 
incubated for 30 min at room temperature. The slide was 
then covered with ECL Clarity (Bio-Rad) and images were 
captured. 
statistical analysis
Cell viability results are presented as the mean ± SD 
of at least three repeated individual experiments for each 
group. Two-group comparisons were performed using 
Student´s t test for paired and unpaired values. In all 
cases, statistical analysis was carried out with XLSTAT 
(Addinsoft™) and P < 0.05 and P < 0.01 were considered 
significant. Results from targeted metabolomics were 
compared by one-way ANOVA with Dunnett’s multiple 
pair-wise comparison tests using a significance threshold 
of 0.05. Other calculations including comparisons with the 
U of Mann-Whitney test and/or correlations were made 
using GraphPad Prism software 6.01 (GraphPad Software, 
San Diego, CA).
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